In a recent video interview with Applied Clinical Trials, Rob DiCicco, vice president of portfolio management at ...

Clinical trials are notoriously expensive, time consuming, and risky. Failure comes at a very high cost (millions of dollars and months of development time wasted), yet studies show that the rate of ...

In today's ACT Brief, we examine quantified reductions in trial visits through selective safety data collection, why protocol ...

Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this ...

Furthermore, increasing complexity in cancer clinical trial design has led to challenges such as protocol deviations, slow enrollment leading to lengthened durations of trial, and escalating costs. By ...

Clinical trial design decisions impact costs, access, and evidence gaps, with breast cancer as the most studied disease globally. The US leads in trial activity, with China showing rapid growth, ...

The number of clinical trials conducted in China is rising dramatically. Historically, scientists have had concerns about the quality of research in China. Researchers within China have pushed to ...

Reliable clinical trial data starts in Phase 1. Learn how early quality signals protect safety and guide confident sponsor decisions.